Moreover, ABCC4 as a biomarker for predicting the treatment response and prognosis of patients with MM who received selinexor was significantly positively correlated with NK cell infiltration and TIM3 expression (Hu et al., 2022). This evidence concerns the gene HAVCR2 and Miyoshi myopathy.